Abstract | AIM: METHODS: Eleven children with chronic liver disease and thirteen age- and sex-matched controls negative for HAV antibodies were vaccinated against hepatitis A after they gave their informed consent. Children with uncontrolled coagulopathy or signs of hepatic decompensation were excluded. The vaccine ( Havrix: 720 ELISA units in 0.5 mL, from GlaxoSmithKline Biologicals) was given intramuscularly in the deltoid in 2 doses 6 mo apart. Children were tested for HAV antibodies one and six months after the 1st dose and one month after the 2nd dose. Total serum bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were determined immediately before and after one month of the 1st dose of the vaccine. RESULTS: Only 7 out of the 11 patients were positive for HAV antibodies after the 1st dose of the vaccine, as compared to 100% of the controls. One month after the 2nd dose, all patients tested were positive for HAV antibodies. No deterioration in liver functions of patients was noted after vaccination. No adverse events, immediate or late, were reported by the mothers after each dose of the vaccine. CONCLUSION:
|
Authors | Hanaa-Mostafa El-Karaksy, Manal-Ismail El-Hawary, Nehal-Mohammad El-Koofy, Rokaya El-Sayed, Mona-Al-Saeed El-Raziky, Samah-Asaad Mansour, Gamal-Mohammad Taha, Fatma El-Mougy |
Journal | World journal of gastroenterology
(World J Gastroenterol)
Vol. 12
Issue 45
Pg. 7337-40
(Dec 07 2006)
ISSN: 2219-2840 [Electronic] United States |
PMID | 17143952
(Publication Type: Journal Article)
|
Chemical References |
- Hepatitis A Antibodies
- Hepatitis A Vaccines
- Alanine Transaminase
|
Topics |
- Adolescent
- Alanine Transaminase
(blood)
- Antibody Formation
- Child
- Child, Preschool
- Female
- Hepatitis A
(immunology)
- Hepatitis A Antibodies
(blood)
- Hepatitis A Vaccines
(standards, therapeutic use)
- Humans
- Liver Diseases
(immunology)
- Liver Function Tests
- Male
- Patient Selection
- Safety
|